DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TREATMENTS
*****************************************************
#Post#: 4132--------------------------------------------------
(Abst.) Rituximab efficacy outlasts B-cell repopulation in MS: T
ime to rethink dosing?
By: agate Date: August 23, 2023, 1:36 am
---------------------------------------------------------
These authors are suggesting that an extended-interval dosing
schedule might be a good idea for patients taking rituximab.
From PubMed (August 22, 2023)--"Efficacy of Rituximab Outlasts
B-Cell Repopulation in Multiple Sclerosis: Time to Rethink
Dosing?"
HTML https://pubmed.ncbi.nlm.nih.gov/37604695/
#Post#: 4241--------------------------------------------------
(JAMA) Potential Medicare and Medicaid savings on anti-CD20 ther
apy for MS
By: agate Date: December 6, 2023, 1:26 am
---------------------------------------------------------
The cost-effectiveness factor plays a part in considering
Ocrevus v. Rituxan. Somehow this comes as no surprise.
From JAMA (November 27, 2023)--"Potential Medicare and Medicaid
Savings on Anti-CD20 Therapy for Multiple Sclerosis":
HTML https://bit.ly/3uJTy8z
#Post#: 4273--------------------------------------------------
(Abst.) Rituximab for MS [advocacy for removing barriers to ritu
ximab for MS]
By: agate Date: January 4, 2024, 12:46 am
---------------------------------------------------------
From PubMed (December 3, 2024)--"Rituximab for multiple
sclerosis":
HTML https://pubmed.ncbi.nlm.nih.gov/38165314/
#Post#: 4355--------------------------------------------------
(Abst.) MS, rituximab, hypogammaglobulinemia, and risk of infect
ions
By: agate Date: March 22, 2024, 1:25 am
---------------------------------------------------------
From PubMed (March 21, 2024)--"Multiple sclerosis, rituximab,
hypogammaglobulinemia, and risk of infections":
HTML https://pubmed.ncbi.nlm.nih.gov/38507657/
#Post#: 4391--------------------------------------------------
(AAN) Comparative effectiveness of standard vs extended rituxima
b dosing intervals in RRMS
By: agate Date: April 23, 2024, 10:32 am
---------------------------------------------------------
From the same researchers, a presentation at the annual AAN
conference (April 13-18)--"Comparative effectiveness of standard
vs extended rituximab dosing intervals in relapsing remitting
multiple sclerosis":
HTML https://index.mirasmart.com/AAN2024/PDFfiles/AAN2024-005480.html
#Post#: 4443--------------------------------------------------
Fatigue and processing speed in PwMS treated w/natalizumab or ri
tuximab
By: agate Date: June 3, 2024, 11:37 am
---------------------------------------------------------
From Multiple Sclerosis Journal--Experimental, Translational,
and Clinical (May 26, 2024)--"A comparative study of fatigue and
processing speed in patients with multiple sclerosis treated
with natalizumab or rituximab":
HTML https://journals.sagepub.com/doi/full/10.1177/20552173241252566
#Post#: 4741--------------------------------------------------
(Abst.) Cochrane Review--Rituximab for people with MS
By: agate Date: March 13, 2025, 10:56 am
---------------------------------------------------------
Cochrane Review of rituximab in PubMed (March 13,
2025)--"Rituximab for people with multiple sclerosis":
HTML https://pubmed.ncbi.nlm.nih.gov/40066932/https://pubmed.ncbi.nlm.nih.gov/40066932/
#Post#: 4759--------------------------------------------------
(Abst.) Early extended-interval dosing of rituximab in MS...
By: agate Date: March 31, 2025, 12:52 am
---------------------------------------------------------
From PubMed (March 30, 2025)--"Early extended interval dosing of
rituximab in multiple sclerosis: A comparative cohort study on
efficacy and safety":
HTML https://pubmed.ncbi.nlm.nih.gov/40157038/
#Post#: 4956--------------------------------------------------
(ECTRIMS) Report on phase 3 trial of annual-dose rituximab
By: agate Date: October 10, 2025, 8:08 pm
---------------------------------------------------------
From Medscape (October 9, 2025):
Annual MS drug effective, affordable, convenient
HTML https://www.medscape.com/viewarticle/annual-multiple-sclerosis-drug-effective-affordable-2025a1000r8s?&icd=login_success_email_match_fpf
#Post#: 5009--------------------------------------------------
(Abst.) Non-inferiority of rituximab vs. ocrelizumab in MS...met
a-analysis
By: agate Date: December 1, 2025, 1:34 am
---------------------------------------------------------
From PubMed (November 30, 2025)--"Non-inferiority of rituximab
versus ocrelizumab in multiple sclerosis (ROC-MS)--an individual
participant data meta-analysis":
HTML https://pubmed.ncbi.nlm.nih.gov/41317517/
*****************************************************
DIR Previous Page
DIR Next Page